基础医学与临床 ›› 2007, Vol. 27 ›› Issue (7): 830-831.

• 研究短文 • 上一篇    下一篇

硫普罗宁在晚期胃癌化疗中增效减毒作用的临床观察

于永强(河北) 李继红 齐维娟 沈金库 高会斌 孙剑经   

  1. 河北北方学院基础医学部生物教研室 河北北方学院基础医学部生物教研室 河北北方学院附属第一医院 消化内科 河北北方学院附属第一医院消化内科 河北北方学院附属第一医院消化内科 河北北方学院附属第一医院 消化内科
  • 收稿日期:2006-06-21 修回日期:2006-10-19 出版日期:2007-07-25 发布日期:2007-07-25
  • 通讯作者: 李继红

Clinical Observation on Tiopronin Increasing the Effect and Attenuating the Toxicity of chemotherapy of advanced gastric cancer

  

  • Received:2006-06-21 Revised:2006-10-19 Online:2007-07-25 Published:2007-07-25

摘要: 目的 探讨凯西莱注射液在联合化疗治疗晚期胃癌的临床作用。方法:选取临床上已失去手术治疗机会的晚期胃癌患者70例。随机分为治疗组35例和对照组35例。对照组单应用FolFox化疗方案治疗,治疗组采用FolFox化疗方案+静脉点滴凯西莱0.3 一日一次,连用五天,一个疗程结束后,评价两组的治疗效果及毒副作用的发生情况[1]。结果:治疗组完全缓解(CR)9例 部分缓解(PR)8例、无变化(NC)15例、 恶化(PD)3例 ,毒副反应发生例数2例。 对照组CR8例 、PR 6例、 NC17例、 PD 4例,毒副反应发生例数8例。 结论:应用FolFox化疗方案联合凯西莱注射液治疗晚期胃癌,可以减少化疗给患者带来的毒副反应,增加晚期胃癌患者对化疗的耐受,提高生存质量,延长生命。

Abstract: Objective:study the clinical function of Tiopronin with comprehensive chemotherapy in the treatment of advanced gastric cancer.Method:70 advanced gastric cancer patients who lost surgical operation treatment opportunity were enrolled into this study. 70 patients with advanced gast ric cancer were divided into two groups randomly(treatment group 35 patients and control group 35 patients).Single apply FolFox in control group;treatment group adopt the FolFox chemotherapy project and Tiopronin 0.3 iv qd d1-d5.Evaluate the curative effects and adverse reactions.Results:9 patients achieved complete response (CR) , 8 patients partial response ( PR) , 15 patients no change ( NC) , 3 patients progression disease ( PD) 2 patients adverse reactions in treatment group and 8 patients achieved complete response (CR) , 6 patients partial response ( PR) , 17 patients no change ( NC) , 4 patients progression disease ( PD) 8 patients adverse reactions in control group.Conclusion: Tiopronin with comprehensive chemotherapy in the treatment of advanced gastric cancer,It can improve efficacy and the quality of life and reduce the adverse reactions of chemotherapy.